|1.||Safarzadeh, Laleh: 1 article (07/2014)|
|2.||Chakravarty, Rubel: 1 article (02/2014)|
|3.||Dash, Ashutosh: 1 article (02/2014)|
|4.||Chakraborty, Sudipta: 1 article (02/2014)|
|5.||Chirayil, Viju: 1 article (02/2014)|
|6.||Vats, Kusum: 1 article (12/2013)|
|7.||Banerjee, Sharmila: 1 article (12/2013)|
|8.||Das, Tapas: 1 article (12/2013)|
|9.||Sarma, Haladhar D: 1 article (12/2013)|
|10.||Pillai, M R A: 1 article (12/2013)|
10/01/2002 - "Thirty-two patients with multiple myeloma were treated with high doses of 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid (DOTMP) and were a subset of patients enrolled in a multicenter phase I/II dose escalation myeloablative trial. "
11/01/2004 - "In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma."
06/01/1995 - "The primary objective of this work was to estimate the absorbed dose distribution to the bone marrow of six multiple myeloma patients who received holmium-166 (166Ho) DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid) for the purpose of bone marrow ablation. "
11/01/2004 - "NeoRx STR 0303: a randomized multicenter study to compare the safety and efficacy of (166) HO-DOTMP plus melphalan to melphalan alone as conditioning for autologous peripheral blood stem cell transplant in subjects with primary refractory multiple myeloma."
|2.||Breast Neoplasms (Breast Cancer)
02/01/2014 - "The suitablility of purified (169)Er for application in radiation synovectomy and bone pain palliation was ascertained by carrying out radiolabeling studies with hydroxypaptite (HA) particles and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaminomethylene phosphonic acid (DOTMP), respectively. "
12/01/2013 - "Therefore, an attempt was made to evaluate the potential of a series of (170)Tm-labeled acyclic (diethylenetriaminepentamethylene phosphonic acid and triethylenetetraminehexamethylene phosphonic acid) and cyclic polyaminopolyphosphonic acids (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid [DOTMP] and 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetramethylene phosphonic acid [CTMP]) toward their use as alternative bone pain palliation agents. "
07/01/2014 - "Different radioisotopes such as P-32, Sm-153, Ho-166, Lu-177, and Re-186 with several chemical ligands as ethylenediaminetetramethylene phosphonic acid (EDTMP), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTMP), and propylenediaminetetramethylene phosphonate (PDTMP) are recommended for bone pain palliation. "
|7.||cyclic 3',5'-thymidine monophosphate (cTMP)
|8.||1-ethyl-2,3-dioxopiperazine (P 32)